DOI: https://doi.org/10.24959/uekj.20.21

Generalization of modern experience of control against the distribution of counterfeit medicines in highly developed countries

S. O. Lebed, А. S. Nemchenko

Abstract


One of the most dangerous forms of counterfeit products is counterfeit medicines. In recent years, there has been a marked increase in the production, trade and consumption of such drugs – often with dangerous and in some cases fatal consequences. The World Health Organization (WHO) receives reports of substandard or counterfeit medicines used in various areas of the health care system, from cancer to contraception. The range of products is counterfeit medicines is not limited to expensive drugs or well-known brands, and is distributed approximately equally between generic drugs and patented products.

Aim. To analyze modern methods of fighting the spread of counterfeit medicines in highly developed countries.

Results. A study of the peculiarities of the organization of state quality control of medicines and pharmaceutical activities in the field of fighting the spread of counterfeit medicines in highly developed countries (USA,Canada,Japan, etc.). Among the methods of counteracting drug falsification and preventing the spread of counterfeit medicines, in the developed economies we studied, the introduction of information technology to collect information about counterfeit medicines, codification of drug packaging, the introduction of software to work in the health care system and directly in pharmacies, raising public awareness about counterfeit medicines.

Conclusions. Factors that contribute to the active spread of counterfeit medicines in developed countries are the uncontrolled activities of online pharmacies, insufficient public awareness of all health risks from the purchase of counterfeit medicines, insufficiently controlled drug supply chains at all stages. The likelihood of an increase in counterfeit medicines acquisition depends on statistical and geospatial factors that should be considered when planning measures to combat counterfeit medicines proliferation. The real state of the counterfeit medicines spread is exacerbated by the fact that none of the countries we studied has signed or ratified the Council of Europe Convention on Counterfeit Medical Products and Similar Crimes Threatening the Health of the Population. Generalization and use of international experience will improve the methods of fighting the drug counterfeiting in Ukraine.

Keywords


counterfeit medicines; modern experience; control of proliferation; highly developed countries

References


Gasiorowski-Denis, E. (2014). Nastuplenie na kontrafakt. Available at: https://www.iso.org/ru/news/2014/01/Ref1809.html.

Informatciia o rezultatakh gosudarstvennogo kontrolia (nadzora) v sfere obrashcheniia lekarstvennykh sredstv za 2018 god. (2019). Available at: http://www.roszdravnadzor.ru/i/upload/images/2019/3/18/1552890383.7477–1–30251.pdf.

Falsyfikatsiia likarskykh zasobiv ta perevirky aptek: holovne z praktyky mizhnarodnoi farmatsevtychnoi spilnoty. (2017). Аптека, 41 (1112). Available at: https://www.apteka.ua/article/430840.

Soloviov, O. S. (2019). Sotsialna farmatsiia v okhoroni zdorov’ia, 5 (3), 57-64. doi: https://doi.org/10.24959/sphhcj.19.158.

Soloviov, O. S. (2019). Upravlinnia, ekonomika ta zabezpechennia yakosti u farmatsii, 3 (59), 28-34. doi: https://doi.org/10.24959/uekj.19.24.

Tolochko,V., Medvedieva, Yu. (2012). Farmatsevtychnyi kur’ier, 2, 16-19.

Kovalenko, I.A. (2018). Falsyfikatsiia ta obih falsyfikovanykh likarskykh zasobiv: kryminalno-pravove doslidzhennia. Odesa: Helvetyka, 232.

Avdieiev, O. R. (2015). Orhanizatsiino-pravovyi mekhanizm protydii kontrabandi narkotychnykh rechovyn ta falsyfikovanykh likarskykh zasobiv v YeS. Naukovyi visnyk Uzhhorodskoho natsionalnoho universytetu. Seriia «Pravo», 34 (3), 8.

Shmatenko, O. P., Holub, A. H., Rudenko, V. V., Takhtaulova, N. O. (2018). Viiskova medytsyna Ukrainy, 18 (3), 86-90.

Chart of signatures and ratifications of Treaty 211. Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health. Available at: https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/211/signatures.

Kogda budet vynesen prigovor falsifikatu? Available at: http://pharma.net.ua/publications/articles/22722-kogda-budet-vynesen-prigovor-falsifikatu (дата обращения: 14.05.2020).

Khoseva, E. N., Morozova, T. E. (2013). Kachestvennaia klinicheskaia praktika, 2, 53-58.

Stukina, V., Dognal, I., Shaloun, Ya. (2017). Evraziiskii Soiuz uchenykh, 6 (39), 61-66.

Cvetanovski, F., Asanova, B., Brezovska, K. (2016). Comparative analysis of EU and USAfalsified medicine legislation. Macedonian pharmaceutical bulletin, 62 (suppl), 681–682. Available at: https://core.ac.uk/download/pdf/80818116.pdf#page=681.

Galt, K. A., Fuji, K. T., Kaufman, T. K., Shah, Sh. R. (2019). Health Information Technology Use and Patient Safety: Study of Pharmacists in Nebraska. Pharmacy, 7 (1), 7. doi: https://doi.org/10.3390/pharmacy7010007.

Abrill, Ju. L., Holt, D. W., Wilson, R. R. (2016). Falsified Medicines in the European Union and North America: What are we doing to Protect Public Health? J Pharmacovigil, 4, 3. doi: 10.4172/2329-6887.1000213.

Cuomo, R. E., Mackey, T. K. An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the US drug supply chain. Available at: https://bmjopen.bmj.com/content/bmjopen/4/12/e006657.full.pdf.

Counterfeit Medicine InAmerica: 9th Annual Drug Abuse Symposium October 29, 2018.

Almuzaini, T., Sammons, H., Choonara, I.(2014). Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013). BMJ Open, 4, e006088. doi: 10.1136/bmjopen-2014-006088.

Counterfeit medications a growing problem in Canada, warns new report. (2018). Available at: https://www.ctvnews.ca/health/counterfeit-medications-a-growing-problem-in-canada-warns-new-report-1.3795239.

Bloomberg. Available at: https://www.bloomberg.com/.

Lai, C. W., Chan, W. K. (2013). Legislations combating counterfeit drugs in Hong Kong. Hong Kong Med J, 19, 286–93. doi: 10.12809/hkmj133841.

Pharmacy & poisons board of Hong Kong. Available at: https://www.ppbhk.org.hk/eng/index.html.

Hensey, C. C., Gwee, A. (2016). Counterfeit drugs: an Australian perspective. MJA, 204 (9). doi: 10.5694/mja16.00105.

May, C. (2019). Counterfeit medicines — fake drugs and falsified medicines — are endangering lives. Available at: https://www.pharmout.net/counterfeit-medications-global-statistics/.

Alfadl, A. A., Ibrahim, M. I. M., Maraghi, F., Mohammad, Kh. S. (2018). General Public and Community Pharmacists Perception on Counterfeit Medicines: A Preliminary Cross-sectional Study in Qatar. J Clin Diagn Res, 12 (1). doi: 10.7860/JCDR/2018/28451.11136.

Alfadl, A. A. R., Ibrahim, M. I. M., Maraghi, F. A., Mohammad, Kh. S. (2016). An Examination of Income Effect on Consumers’ Ethical Evaluation of Counterfeit Drugs Buying Behaviour: A Cross-Sectional Study in Qatarand Sudan. J Clin Diagn Res, 10 (9), IC01–IC04. doi: 10.7860/JCDR/2016/19526.8410.

Daisaku, Sato. (2014). Counterfeit medicines--Japanand the world. Yakugaku Zasshi, 134 (2), 213-222. doi: 10.1248/yakushi.13-00230-3.

Almuzaini, T., Sammons, H., Choonara, I.(2013). Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011). BMJ Open, 3, e002924. doi: 10.1136/bmjopen-2013-002924.

Houlton, S. (2018). Tackling the problem of falsified medicines in the UK. Prescriber, 29 (7), 33-35. doi: https://doi.org/10.1002/psb.1690.

Robles, Y. R., Casauay, J. F. C., Bulatao, B. P. I. (2016). Addressing the Barriers to Effective Monitoring, Reporting and Containment of Spurious/Substandard/Falsely-labelled/ Falsified/Counterfeit Medical Products through Sustainable Multi-stakeholder Collaboration and Community/Consumer-based Interventions. A report prepared for the Medicines Transparency Alliance.Philippines, 94.


GOST Style Citations


1. Gasiorowski-Denis E. Наступление на контрафакт. URL: Gasiorowski-Denis E. Наступление на контрафакт. URL: https://www.iso.org/ru/news/2014/01/Ref1809.html (Date of access: 14.05.2020).

 

2. Информация о результатах государственного контроля (надзора) в сфере обращения лекарственных средств за 2018 год. URL: http://www.roszdravnadzor.ru/i/upload/images/2019/3/18/1552890383.7477–1–30251.pdf (Date of access: 14.05.2020).

 

3. Фальсифікація лікарських засобів та перевірки аптек: головне з практики міжнародної фармацевтичної спільноти. Аптека. 2017. № 41 (1112). URL: https://www.apteka.ua/article/430840 (дата звернення: 14.05.2020).

 

4. Соловйов О. С. Конвенція «Медікрим» як інструмент протидії підробленню медичної продукції в Україні. Соціальна фармація в охороні здоров’я. 2019. Т. 5, № 3. С. 57-64. DOI: https://doi.org/10.24959/sphhcj.19.158 (дата звернення: 14.05.2020).

 

5. Соловйов О. С. Міжнародний механізм протидії фальсифікації медичної продукції як засіб підвищення якості у фармації України. Управління, економіка та забезпечення якості у фармації. 2019. № 3 (59). С. 28-34. DOI: https://doi.org/10.24959/uekj.19.24 (дата звернення: 14.05.2020).

 

6. Толочко В., Медведєва Ю. Вивчення досвіду Європейського Союзу щодо боротьби з фальсифікованими лікарськими засобами, які реалізовуються через інтернет‑аптеки. Фармацевтичний кур’єр. 2012. № 2. С. 16-19.

 

7. Коваленко І. А. Фальсифікація та обіг фальсифікованих лікарських засобів: кримінально-правове дослідження : монографія. Одеса : Гельветика, 2018. 232 с.

 

8. Авдєєв О. Р. Організаційно-правовий механізм протидії контрабанді наркотичних речовин та фальсифікованих лікарських засобів в ЄС. Науковий вісник Ужгородського національного університету. Серія «Право». 2015. Вип. 34, т. 3. С. 8.


9. Шматенко О. П., Голуб А. Г., Руденко В. В., Тахтаулова Н. О., Рум’янцев Ю. В. Проблеми розповсюдження фальсифікованих лікарських засобів та шляхи їх вирішення. Військова медицина України. 2018. Т. 18, № 3. С. 86-90.

 

10. Chart of signatures and ratifications of Treaty 211. Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health. URL: https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/211/signatures (Date of access: 14.05.2020).


11. Когда будет вынесен приговор фальсификату? URL: http://pharma.net.ua/publications/articles/22722-kogda-budet-vynesen-prigovor-falsifikatu (дата обращения: 14.05.2020).


12. Хосева Е. Н., Морозова Т. Е. Организация контроля качества, эффективности и безопасности лекарственных средств на государственном уровне за рубежом и в России. Качественная клиническая практика. 2013. № 2. С. 53-58.


13. Стукина В., Догнал Й., Шалоун Я. Сравнительный анализ регулирования сериализации лекарственных препаратов в Европейском Союзе и США: технологи и право. Евразийский Союз ученых. 2017. № 6 (39). С. 61-66.

 

14. Cvetanovski F., Asanova B., Brezovska K. Comparative analysis of EU and USAfalsified medicine legislation. Macedonian pharmaceutical bulletin. 2016. Vol. 62 (suppl). P. 681–682. URL: https://core.ac.uk/download/pdf/80818116.pdf#page=681 (Date of access: 14.05.2020).


15. Galt K. A., FujiK. T., Kaufman T. K., Shah Sh. R. Health Information Technology Use and Patient Safety: Study of Pharmacists in Nebraska. Pharmacy. 2019. 7 (1). P. 7. DOI: https://doi.org/10.3390/pharmacy7010007 (Date of access: 14.05.2020).


16. Abrill Ju. L., Holt D. W., Wilson R. R. Falsified Medicines in the European Union andNorth America: What are we doing to Protect Public Health? J Pharmacovigil. 2016. Vol 4. P. 3. DOI: 10.4172/2329-6887.1000213 (Date of access: 14.05.2020).


17. Cuomo R. E., Mackey T. K. An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the USdrug supply chain. URL: https://bmjopen.bmj.com/content/bmjopen/4/12/e006657.full.pdf (Date of access: 14.05.2020).


18. Counterfeit Medicine InAmerica: 9th Annual Drug Abuse Symposium October 29, 2018.


19. Almuzaini T., Sammons H., Choonara I. Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013). BMJ Open. 2014. Vol. 4. P. e006088. DOI: 10.1136/bmjopen-2014-006088 (Date of access: 14.05.2020).

 

20. Counterfeit medications a growing problem in Canada, warns new report. 2018. URL: https://www.ctvnews.ca/health/counterfeit-medications-a-growing-problem-in-canada-warns-new-report-1.3795239 (Date of access: 14.05.2020).


21. Bloomberg. URL: https://www.bloomberg.com/ (Date of access: 14.05.2020).


22. Lai C. W., Chan W. K. Legislations combating counterfeit drugs in Hong Kong. Hong Kong Med J. 2013. Vol. 19. P. 286–93. DOI: 10.12809/hkmj133841 (Date of access: 14.05.2020).


23. Pharmacy & poisons board of Hong Kong. URL: https://www.ppbhk.org.hk/eng/index.html (Date of access: 14.05.2020).


24. Hensey C. C., Gwee A. Counterfeit drugs: an Australian perspective. MJA. 2016. Vol. 204 (9). DOI: 10.5694/mja16.00105 (Date of access: 14.05.2020).


25. May C. Counterfeit medicines — fake drugs and falsified medicines — are endangering lives. 2019.07.03. URL: https://www.pharmout.net/counterfeit-medications-global-statistics/ (Date of access: 14.05.2020).


26. Alfadl A. A.,  Ibrahim M. I. M., Maraghi F.,  Mohammad Kh. S. General Public and Community Pharmacists Perception on Counterfeit Medicines: A Preliminary Cross-sectional Study in Qatar. J Clin Diagn Res. 2018. Vol. 12 (1). DOI: 10.7860/JCDR/2018/28451.11136 (Date of access: 14.05.2020).


27. Alfadl A. A. R., Ibrahim M. I. M., Maraghi F. A., Mohammad Kh. Shhab. An Examination of Income Effect on Consumers’ Ethical Evaluation of Counterfeit Drugs Buying Behaviour: A Cross-Sectional Study in Qatar and Sudan. J Clin Diagn Res. 2016. Vol. 10 (9). P. IC01–IC04. DOI: 10.7860/JCDR/2016/19526.8410 (Date of access: 14.05.2020).


28. Daisaku Sato. Counterfeit medicines--Japanand the world. Yakugaku Zasshi. 2014. Vol. 134 (2). P. 213-222. DOI: 10.1248/yakushi.13-00230-3 (Date of access: 14.05.2020).


29. Almuzaini T., Sammons H., Choonara I. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011). BMJ Open. 2013.  Vol. 3. P. e002924. DOI: 10.1136/bmjopen-2013-002924 (Date of access: 14.05.2020).


30. Houlton S. Tackling the problem of falsified medicines in the UK. Prescriber. 2018. Vol. 29, Issue 7. P. 33-35. DOI: https://doi.org/10.1002/psb.1690 (Date of access: 14.05.2020).


31. Robles Y. R., Casauay J. F. C., Bulatao B. P. I. Addressing the Barriers to Effective Monitoring, Reporting and Containment of Spurious/Substandard/Falsely-labelled/ Falsified/Counterfeit Medical Products through Sustainable Multi-stakeholder Collaboration and Community/Consumer-based Interventions. A report prepared for the Medicines Transparency Alliance.Philippines, 2016. 94 p.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Manag. econ. qual. assur. pharm.

ISSN 2519-8807 (Online), ISSN 2311-1127 (Print)